Custom Search


Tuesday 26 June 2007

Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS).

By: Bernardo M, Azanza JR, Rubio-Terrés C, Rejas J.

Actas Esp Psiquiatr 2007 Jul-Aug;35(4):259-62

OBJECTIVE: Estimate the cost-effectiveness of the prevention of relapse of schizophrenia in the ZEUS (Ziprasidone Extended Use in Schizophrenia Study) longitudinal study that compares ziprasidone with the option of not treating. METHODS: One year of treatment was analyzed using the randomized clinical trial data (ZEUS study) with a deterministic model, having cost-effectiveness analysis type, conducted from the perspective of the National Health Care System (NHCS). RESULTS: Additional mean yearly cost for worsening avoided with ziprasidone was 186 Pounds for the mean dose, ranging from -556 Pounds (savings) with the 80 mg/day dose and 1,014 Pounds with 160 mg/day, which was always lower than the minimum cost of a relapse (2,830 Pounds), considered as threshold value to establish cost-effectiveness of treatment with ziprasidone. CONCLUSIONS: Prevention of relapse of schizophrenia with long-term ziprasidone is cost-effective in comparison with the option of not treating. Treatment with ziprasidone avoids relapse episodes at a reasonable cost, generating savings for the NHCS.

Use of this site is subject to the following terms of use